BR0211494A - Adesinas de meningococo nada, app e orf 40 - Google Patents

Adesinas de meningococo nada, app e orf 40

Info

Publication number
BR0211494A
BR0211494A BR0211494-1A BR0211494A BR0211494A BR 0211494 A BR0211494 A BR 0211494A BR 0211494 A BR0211494 A BR 0211494A BR 0211494 A BR0211494 A BR 0211494A
Authority
BR
Brazil
Prior art keywords
app
revealed
adhesins
orf
nothing
Prior art date
Application number
BR0211494-1A
Other languages
English (en)
Inventor
Maria Beatrice Arico
Maurizio Comanducci
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0118401A external-priority patent/GB0118401D0/en
Priority claimed from GBGB0121591.2A external-priority patent/GB0121591D0/en
Priority claimed from GB0211025A external-priority patent/GB0211025D0/en
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BR0211494A publication Critical patent/BR0211494A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"ADESINAS DE MENINGOCOCO NADA, APP e ORF 40". NadA, App e ORF40 funcionam como adesinas em N. meningitidis. A adesão pode ser modulada tendo como alvo essas três proteinas. Variantes alélicas de NadA são reveladas. Clivagem autoproteolitica de App é revelada, assim como a remoção da atividade por mutagênese. App é processada e secretada em meio de cultura quando expressa em E. coli. Proteínas App maduras são reveladas. Mutantes knockout são revelados. Vesículas de hospedeiros diferentes de Neisseria com expressão heteróloga de adesina são reveladas.
BR0211494-1A 2001-07-27 2002-07-26 Adesinas de meningococo nada, app e orf 40 BR0211494A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0118401A GB0118401D0 (en) 2001-07-27 2001-07-27 Meningococcus data
GBGB0121591.2A GB0121591D0 (en) 2001-09-06 2001-09-06 Hybrid and tandem expression of neisserial proteins
GB0211025A GB0211025D0 (en) 2002-05-14 2002-05-14 Meningococcus adhesins
PCT/IB2002/003396 WO2003010194A2 (en) 2001-07-27 2002-07-26 Meningococcus adhesins nada, app and orf 40

Publications (1)

Publication Number Publication Date
BR0211494A true BR0211494A (pt) 2004-08-17

Family

ID=27256234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211494-1A BR0211494A (pt) 2001-07-27 2002-07-26 Adesinas de meningococo nada, app e orf 40

Country Status (14)

Country Link
US (3) US20050232936A1 (pt)
EP (2) EP2248822B1 (pt)
JP (3) JP4592284B2 (pt)
AT (1) ATE469915T1 (pt)
AU (1) AU2002355197A1 (pt)
BR (1) BR0211494A (pt)
CA (1) CA2452836C (pt)
CY (2) CY1111715T1 (pt)
DE (1) DE60236596D1 (pt)
DK (1) DK2248822T3 (pt)
ES (1) ES2615362T3 (pt)
MX (1) MXPA04000653A (pt)
PT (1) PT2248822T (pt)
WO (1) WO2003010194A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
ES2304065T3 (es) 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
AU783894B2 (en) 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN100473663C (zh) 2000-02-28 2009-04-01 启龙股份公司 奈瑟球菌蛋白质的异源表达
CA2416137C (en) 2000-07-27 2013-01-29 Dan Granoff Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4592284B2 (ja) 2001-07-27 2010-12-01 カイロン ソチエタ ア レスポンサビリタ リミタータ 髄膜炎菌付着因子
JP2006500963A (ja) * 2002-08-02 2006-01-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
GB0315022D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Virulence-associated adhesins
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0415160D0 (en) * 2004-07-06 2004-08-11 Chiron Srl Inhibitors of bacterial infection
EP2682126B1 (en) 2005-01-27 2016-11-23 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
WO2007066226A2 (en) * 2005-12-06 2007-06-14 Universita Degli Studi Di Padova Methods and compositions relating to adhesins as adjuvants
CN102227638B (zh) * 2008-09-30 2015-05-20 Abbvie公司 Rna展示的改良方法
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
AU2011300418B2 (en) * 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
JP2015521595A (ja) * 2012-06-14 2015-07-30 ノバルティス アーゲー 血清群ｘ髄膜炎菌のためのワクチン
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
WO2023187743A1 (en) * 2022-03-31 2023-10-05 The University Of Queensland Improved chimeric polypeptides and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
PT74811B (en) 1981-04-29 1983-10-26 Biogen Nv Bacillus cloning vectors recombinant dna molecules bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
ATE246244T1 (de) 1988-01-29 2003-08-15 Aventis Pasteur Rekombinante cmv-neutralisierungsproteine
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6610539B1 (en) 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6300318B1 (en) 1997-09-16 2001-10-09 Peter E. Nielsen Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
NZ338004A (en) 1998-01-30 2001-08-31 Suntory Ltd Process for producing peptide with glucagon like peptide-1 (GLP-1) activity by incorporating a protective and helper component to facilitate purification
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
ES2304065T3 (es) * 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
GB9810276D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
GB9818004D0 (en) 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
BR0010361A (pt) 1999-04-30 2003-06-10 Chiron Corp Seq ências genÈmicas de neisseria e uso destas
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
AU783894B2 (en) 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
RU2002117308A (ru) 1999-11-29 2004-03-10 Чирон Спа (It) 85 кДа АНТИГЕН NEISSERIA
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK2289545T3 (en) * 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
CN100473663C (zh) 2000-02-28 2009-04-01 启龙股份公司 奈瑟球菌蛋白质的异源表达
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4592284B2 (ja) 2001-07-27 2010-12-01 カイロン ソチエタ ア レスポンサビリタ リミタータ 髄膜炎菌付着因子
JP2006500963A (ja) 2002-08-02 2006-01-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
AU2003274511B2 (en) * 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos

Also Published As

Publication number Publication date
CA2452836A1 (en) 2003-02-06
JP2010268801A (ja) 2010-12-02
CA2452836C (en) 2012-11-27
US20050232936A1 (en) 2005-10-20
EP2248822A2 (en) 2010-11-10
US9249197B2 (en) 2016-02-02
JP2005503785A (ja) 2005-02-10
EP2248822A3 (en) 2011-04-13
PT2248822T (pt) 2017-02-14
ES2615362T3 (es) 2017-06-06
CY1111715T1 (el) 2015-10-07
MXPA04000653A (es) 2004-11-22
AU2002355197A1 (en) 2003-02-17
DE60236596D1 (de) 2010-07-15
JP4902678B2 (ja) 2012-03-21
JP4592284B2 (ja) 2010-12-01
EP1412381A2 (en) 2004-04-28
US20100221256A1 (en) 2010-09-02
EP1412381B1 (en) 2010-06-02
JP2009148279A (ja) 2009-07-09
ATE469915T1 (de) 2010-06-15
DK2248822T3 (en) 2017-02-13
US20140294884A1 (en) 2014-10-02
EP2248822B1 (en) 2016-11-23
CY1118628T1 (el) 2017-07-12
WO2003010194A2 (en) 2003-02-06
WO2003010194A3 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
BR0211494A (pt) Adesinas de meningococo nada, app e orf 40
BRPI0407352A (pt) Composição para o cuidado oral, e, métodos para efetuar a estabilidade aumentada em uma composição oral contendo enzimas, e para a preparação de uma composição para o cuidado oral aquosa
BRPI0413007A (pt) bactéria escherichia, e, método de produzir l-lisina ou l-treonina
WO2007109430A3 (en) User interface and method therefor
BRPI0407603A (pt) sistema para monitorar e método para apresentar informação de consumo de utilidade
PT1436381E (pt) Celulas estaminais desdiferenciadas e programaveis de origem monocitaria e sua producao e utilizacao
HK1075403A1 (en) Treatment of mastalgia with 4-hydroxy tamoxifen
MY138891A (en) Chewable antiplaque confectionery dental composition
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
GB2415437A (en) Differentiation of human embryonic stem cells to cardiomyocytes
AU2003277070A1 (en) Reducing facial ageing and appliance therefor
AU5384799A (en) Silicon-containing titanium dioxyde, method for preparing the same and catalyticcompositions thereof
WO2003100574A3 (en) Dental appliances and systems and methods for distributing dental appliances
NZ508323A (en) Neisseria meningitidis BASB029 polynucleotides and polypeptides and methods for their production
BR0114477A (pt) Produção de etanol
MXPA04005007A (es) Prenda absorbente con ingredientes para bienestar de la piel incorporados.
NZ507077A (en) A vaccine comprising a bacterium that has an aroC/ompF/ompC combination mutation and optionally a mutation in a fourth gene
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
AU2002359244A1 (en) Imaging the activity of extracellular proteases in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases
ATE491025T1 (de) Subtilasevarianten mit veränderter immunogenität
WO2005049817A3 (en) Self-cleaving ribozymes and uses thereof
AU3903701A (en) Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase
FR2696187B1 (fr) Nouvelles souches hybrides d'Agaricus bisporus, dont la germination des spores fournit majoritairement des homocaryons, leur obtention et leur utilisation.
PL365040A1 (en) Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. (IT)

Free format text: ALTERADO DE: CHIRON S.R.L.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2316 DE 26-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.